IMPORTANCE Neovascular age-related macular degeneration (nvAMD) is a leading cause of vision loss. The optimal screening protocol to detect choroidal neovascularization (CNV) in fellow eyes of patients undergoing treatment for unilateral CNV has not been determined.
A ge-related macular degeneration (AMD) is the most common cause of vision loss among elderly Americans. 1 While anti-vascular endothelial growth factor (VEGF) agents have revolutionized the treatment of neovascular AMD (nvAMD), 2, 3 an effective means of treating nonneovascular AMD has eluded the ophthalmic community. Thus, patients with nvAMD in one eye and nonneovascular AMD in the fellow eye must wait until they develop signs of nvAMD in the fellow eye before definitive treatment can be initiated.
The time interval at which to screen patients who are being actively treated for nvAMD in one eye but who have nonneovascular AMD in the fellow eye is somewhat controversial. Some physicians examine and obtain optical coherence tomography (OCT) images of both eyes at every office visit to check for evidence of conversion from nonneovascular AMD to nvAMD. Other physicians treat the eye with nvAMD on a fixed, as required, or treat-and-extend protocol and only examine the fellow eye at some other interval (eg, every 3, 6, or 12 months).
Data from the ForeseeHome trial, 4 the Submacular Surgery Trial, 5 the MARINA study, 6 and others 7 suggest that timely identification and treatment of choroidal neovascularization (CNV) leads to better visual outcomes for patients with nvAMD. Several investigations have shown that better baseline visual acuity (VA) is a predictor of better posttreatment VA, which again highlights the importance of early detection and treatment of CNV. 8, 9 In our practice, we routinely examine and obtain OCT imaging of fellow eyes with nonneovascular AMD in patients who are being actively treated for nvAMD in the other (index) eye. The purpose of the present analysis was to determine if fellow eyes fared better in terms of posttreatment VA after conversion to nvAMD than their index eye counterparts. We hypothesized that visual outcomes would be superior in fellow eyes compared with index eyes because of earlier detection and treatment of CNV in the fellow eyes. 
Methods

Results
There were 264 patients who met the study eligibility criteria. Of these, 197 (74.6%) were women and 253 (95.8%) were white, and the mean (SD) age was 79.1 (8. Meaning Fellow eyes of patients with established neovascular age-related macular degeneration achieved better VA than index eyes after an equivalent follow-up period, which may be attributed to earlier diagnosis and treatment of choroidal neovascularization in fellow eyes compared with index eyes. vs 35%, respectively) and at equivalent postconversion follow-up visits (71% vs 76%). There was no difference in the mean number of anti-VEGF injections received by index and fellow eyes during equal periods of follow-up (10.0 vs 9.7 injections, respectively; difference, 0.23; 95% CI, −0.95 to 0.49; P = .53).
Discussion
Fellow eyes of previously treated patients with nvAMD achieved better final VA than their index eye counterparts after an equivalent amount of follow-up. There was no difference in the mean number of anti-VEGF injections between index and fellow eyes, and the duration of nvAMD was controlled for. Thus, our results suggest that early detection and treatment of newly diagnosed CNV in fellow eyes of previously or concurrently treated patients with nvAMD may result in superior visual outcomes in fellow eyes compared with index eyes. The idea that prompt detection and treatment of CNV may preserve VA is not novel. 5 However, despite the results of prior studies that show a benefit of early diagnosis and treatment of nvAMD, 4 some practitioners still do not consistently screen fellow eyes with nonneovascular AMD for conversion to nvAMD at each index eye treatment session. Our study suggests that it may be prudent to screen the fellow eye with nonneovascular AMD with an OCT and fundus examination at every office visit while the index eye with nvAMD is receiving anti-VEGF injections. If this is done, CNV can be detected early in the fellow eye and treated before vision loss occurs.
Strengths and Limitations
The main strengths of this study are the large number of patients included in the analysis and the paired comparison of fellow and index eye data that allows patients to serve as their own internal control, thus reducing potential variables that could influence final visual outcome, such as differences in physician treatment strategies and medical and ocular comorbidities. However, the retrospective nature of the study precludes us from eliminating all potential confounders and biases from the analyses. Also, the data presented are from a single vitreoretinal practice and thus may not be generalizable to all practicing vitreoretinal specialists who may care for patients with AMD with different demographic makeups and/or lesion characteristics.
Conclusions
We conclude that routine screening for new CNV in fellow eyes with nonneovascular AMD of patients currently being treated for nvAMD at each office visit may be worthwhile because it could lead to the early detection and treatment of CNV when VA is still good, thus preserving VA among fellow eyes. Future studies may aim to determine whether the frequent office visits, VA measurements, or OCT testing might be responsible for the detection of new CNV at a better level of VA. Author Contributions: Drs Stem and Hassan had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. 
